Title |
The promise of the anti-idiotype concept
|
---|---|
Published in |
Frontiers in oncology, January 2012
|
DOI | 10.3389/fonc.2012.00196 |
Pubmed ID | |
Authors |
Thomas Kieber-Emmons, Bejatohlah Monzavi-Karbassi, Anastas Pashov, Somdutta Saha, Ramachandran Murali, Heinz Kohler |
Abstract |
A basic tenet of antibody-based immunity is their specificity to antigenic determinates from foreign pathogen products to abnormal cellular components such as in cancer. However, an antibody has the potential to bind to more than one determinate, be it an antigen or another antibody. These observations led to the idiotype network theory (INT) to explain immune regulation, which has wax and waned in enthusiasm over the years. A truer measure of the impact of the INT is in terms of the ideas that now form the mainstay of immunological research and whose roots are spawned from the promise of the anti-idiotype concept. Among the applications of the INT is understanding the structural implications of the antibody-mediated network that has the potential for innovation in terms of rational design of reagents with biological, chemical, and pharmaceutical applications that underlies concepts of reverse immunology which is highlighted herein. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 45 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 20% |
Student > Ph. D. Student | 8 | 18% |
Student > Master | 7 | 16% |
Student > Bachelor | 5 | 11% |
Other | 3 | 7% |
Other | 4 | 9% |
Unknown | 9 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 12 | 27% |
Medicine and Dentistry | 7 | 16% |
Agricultural and Biological Sciences | 5 | 11% |
Immunology and Microbiology | 5 | 11% |
Engineering | 2 | 4% |
Other | 3 | 7% |
Unknown | 11 | 24% |